BMY Bristol-Myers Squibb Company

  1. Stocks
  2. Healthcare
  3. NYSE: BMY

Price (delayed)

$64.65

Market cap

$132.06B

P/E Ratio

14.21

Dividend/share

$2.51

EPS

$4.55

Enterprise value

$166.46B

?
Relative Growth: Rel. Growth: 70
Relative Strength: Rel. Strength: 67
Relative Valuation: Rel. Valuation: 85
Relative Profitability: Rel. Profitability: 96

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

Highlights
The net income has surged by 84% year-on-year and by 28% since the previous quarter
Bristol-Myers Squibb's EPS has surged by 83% YoY and by 27% QoQ
Sector: Healthcare
Industry: Drug Manufacturers - General
Website: http://www.bms.com
Peers: MRK LLY PFE NVS

Key stats

What are the main financial stats of BMY

BMY stock price

How has the Bristol-Myers Squibb stock price performed over time
Intraday
1.49%
1 week
0.78%
1 month
8.95%
1 year
35.11%
YTD
19.86%
QTD
12.2%

Financial performance

How have Bristol-Myers Squibb's revenue and profit performed over time
Revenue
$49.19B
Gross profit
$34.51B
Operating income
$11.91B
Net income
$9.28B
Gross margin
70.2%
Net margin
18.9%
The net income has surged by 84% year-on-year and by 28% since the previous quarter
The operating income has surged by 81% year-on-year and by 24% since the previous quarter
BMY's net margin has soared by 78% year-on-year and by 26% since the previous quarter
The operating margin has surged by 75% year-on-year and by 22% since the previous quarter

Price vs fundamentals

How does BMY's price correlate with its fundamentals

Growth

What is Bristol-Myers Squibb's growth rate over time

Valuation

What is Bristol-Myers Squibb stock price valuation
BMY P/E details
P/E
14.21
P/B
5.92
P/S
2.68
EV/EBIT
13.97
EV/EBITDA
11.03
EV/Sales
3.38
Bristol-Myers Squibb's EPS has surged by 83% YoY and by 27% QoQ
The stock's price to earnings (P/E) is 6% less than its last 4 quarters average of 15.1
Bristol-Myers Squibb's equity has increased by 28% YoY and by 11% from the previous quarter
BMY's P/B is 14% above its 5-year quarterly average of 5.2 and 6% above its last 4 quarters average of 5.6
The price to sales (P/S) is 17% more than the last 4 quarters average of 2.3 and 3.1% more than the 5-year quarterly average of 2.6
The company's revenue rose by 3.1% YoY

Efficiency

How efficient is Bristol-Myers Squibb business performance
Bristol-Myers Squibb's ROA has soared by 91% YoY and by 30% from the previous quarter
BMY's return on invested capital has surged by 84% year-on-year and by 22% since the previous quarter
Bristol-Myers Squibb's return on sales has surged by 75% YoY and by 22% QoQ
The ROE has soared by 58% YoY and by 20% from the previous quarter

Dividends

What is BMY's dividend history
Dividend details
DPS
$2.51
Dividend yield
3.88%
Payout ratio
55.2%
Recent dividends

Special dividends are included in TTM DPS and yield

Financial health

How did Bristol-Myers Squibb financials performed over time
BMY's total assets is 34% greater than its total liabilities
The quick ratio has increased by 27% YoY and by 12% QoQ
Bristol-Myers Squibb's current ratio has increased by 26% YoY and by 8% from the previous quarter
BMY's debt is 93% greater than its equity
The company's debt to equity fell by 32% YoY and by 13% QoQ
Bristol-Myers Squibb's equity has increased by 28% YoY and by 11% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.